Sermorelin Strength: 15 mg A higher-strength option for patients seeking a more advanced longevity and wellness-focused protocol
8 and 9), potentially due to the weaker interactions between Cagri and ECL3
All data were analyzed using SPSS 23.0 software (IBM Corp., Armonk) and Graphpad Prism 5.0 (GraphPad Software)
Benefits (Research Focus) FOXO4-p53 PPI research studied as a selective disruptor of the FOXO4p53 protein-protein interaction in cellular research models p53 transactivation domain pharmacology investigated for targeting the p53 transactivation domain surface in PPI inhibitor research Cellular senescence research explored for senescence-associated apoptosis pathway endpoints in cell culture research models D-retro-inverso peptide chemistry examined for peptidase resistance and SAR studies of D-amino-acid sequence-reversed peptide design SASP marker research researched for senescence-associated secretory phenotype marker dynamics (p16, IL-6) in cell research What Researchers Look At FOXO4-p53 binding interface analysis and competitive PPI disruption assays p16 INK4a , IL-6, and other SASP marker expression in senescent cell research models Apoptosis induction (caspase activation, Annexin V staining) in senescent versus non-senescent cell research D-retro-inverso versus L-peptide comparative stability and biological activity research Comparative pharmacology versus other senolytic research compounds and PPI inhibitors Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: FOXO4-DRI Synonyms: FOXO4 D-retro-inverso peptide
Fillerfy GHK-Cu 50MG is a premium copper peptide solution formulated for professional aesthetic, skincare, wellness, and regenerative markets
